TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius engineers. Gregg Higgs is owner of Fab Fours, a car accessory manufacturer that has ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

The Kymera powered body board we looked at back in 2010 has been refined and is nearing commercial availability.

Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Kymera Therapeutics announces $250.8 million public offering of common stock and pre-funded warrants to advance its biopharmaceutical programs.

Sanofi will advance Kymera's KT-485 into clinical trials while discontinuing KT-474, offering significant collaboration milestones.